John Cunningham Virus and Progressive Multifocal Leukoencephalopathy: A Falsely Played Diagnosis [PDF]
DiseasesProgressive Multifocal Leukoencephalopathy (PML) is a possibly fatal demyelinating disease and John Cunningham Polyomavirus (JCPyV) is believed to cause this condition.
Dimitra S. Mouliou
doaj +5 more sources
COS-7-based model: methodological approach to study John Cunningham virus replication cycle [PDF]
Virology Journal, 2018 John Cunningham virus (JCV) is a human neurotropic polyomavirus whose replication in the Central Nervous System (SNC) induces the fatal demyelinating disease, progressive multifocal leukoencephalopathy (PML).
C. Prezioso +6 more
doaj +7 more sources
A Case of John Cunningham Virus Induced Rhombencephalitis after Rituximab Therapy for Idiopathic Thrombocytopenic Purpura [PDF]
Case Reports in Infectious Diseases, 2021 Background. John Cunningham virus (JCV) is known to cause progressive multifocal leukoencephalopathy (PML) in immuno-compromised patients due to lytic infection of oligodendrocytes and astrocytes. Rarely, it may also present as granule cell neuronopathy (
Silpita Katragadda +4 more
doaj +7 more sources
Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study [PDF]
Brain and Behavior, 2019 Introduction Determination of antibodies against the John Cunningham virus (JCV) is an important tool for risk stratification in Natalizumab‐treated multiple sclerosis (MS) patients.
Michael Auer +7 more
doaj +6 more sources
Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. [PDF]
Curr Neuropharmacol, 2022 Background: Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic infection caused by John Cunningham virus (JCV) reactivation, potentially associated with natalizumab (NTZ) treatment for Multiple Sclerosis (MS).
Sgarlata E +6 more
europepmc +4 more sources
Rates of John Cunningham virus seroconversion greatly reduced in natalizumab-treated patients during COVID-19-related lockdowns. [PDF]
Eur J Neurol, 2023 This study was undertaken to retrospectively compare rates of John Cunningham virus (JCV) seroconversion in natalizumab‐treated patients before and during COVID‐19‐related community restrictions.
Dwyer C, Sharmin S, Kalincik T.
europepmc +4 more sources
John Cunningham Virus seroconversion during natalizumab treatment
ABCS Health SciencesIntroduction: Multiple sclerosis is a progressive disease that is difficult to predict, originating in cases of disability. Natalizumab is a highly effective disease-modifying therapy but is associated with greater John Cunningham virus (JCV ...
Erica Freire de Vasconcelos-Pereira +10 more
doaj +3 more sources
Stroke Mimics: A Case of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy. [PDF]
CureusProgressive multifocal leukoencephalopathy (PML) is a rare, often fatal neurological disorder caused by the John Cunningham virus (JCV). It affects immunocompromised individuals, leading to brain demyelination.
Kamran HS, Khan A, Ling CSB, Kausar S.
europepmc +4 more sources
Unveiling the Enigma: John Cunningham Virus-Associated Progressive Multifocal Leukoencephalopathy in an Immunocompetent Individual. [PDF]
CureusProgressive multifocal leukoencephalopathy (PML) is considered an often fatal, demon-leading disease primarily associated with immunosuppression. Immunocompromised individuals predominantly exhibit this manifestation, while immunocompatible patients ...
Arumugam P +4 more
europepmc +4 more sources
High Seroprevalence and Index of Anti-John-Cunningham Virus Antibodies in Korean Patients with Multiple Sclerosis. [PDF]
J Clin Neurol, 2019 Background and Purpose The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab.
Kim SH +6 more
europepmc +5 more sources